Calton & Associates, Inc. Nektar Therapeutics Transaction History
Calton & Associates, Inc.
- $542 Million
- Q2 2025
Shares
2 transactions
Others Institutions Holding NKTR
# of Institutions
20Shares Held
16.1MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY15.2MShares$952 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY491KShares$30.9 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL327KShares$20.5 Million0.0% of portfolio
-
Vista Wealth Management Group, LLC51.5KShares$3.23 Million0.0% of portfolio
-
Frontier Wealth Management LLC Kansas City, MO12KShares$753,6000.0% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $11.8B
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...